RxDoctor Payments Data

Zachary-Ross Goodwin, MD

Neurology · Lacombe, LANPI 1699206805

Payments from drug & device makers

$6,211in general payments, 2019–2025

Across 303 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$881
  • AbbVie$595
  • AstraZeneca$579
  • Genentech USA, Inc.$413
  • UCB, Inc.$372
  • Amgen$323
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$401%
  • Food & beverage$6,11498%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,211 in reported general payments places this provider in the 60th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$86,003
Medicare patients
285
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4623$387,074
NuplazidPimavanserin Tartrate17$86,493
KeppraLevetiracetam12$24,932
OngentysOpicapone21$15,285
Emgality PenGalcanezumab-Gnlm21$14,305
Aimovig AutoinjectorErenumab-Aooe12$8,696
Lacosamide111$6,903
Donepezil Hcl251$2,026
Levetiracetam89$1,849
Memantine Hcl72$1,350
Gabapentin95$1,315
Propranolol Hcl55$1,273
Primidone34$1,130
Quetiapine Fumarate68$1,092
Pyridostigmine Bromide14$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$187$387,07423 claims
Acadia Pharmaceuticals IncNuplazid$881$86,49317 claims
Neurocrine Biosciences, Inc.Ongentys$33$15,28521 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$19$1,83027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 225 neurology providers in Louisiana.

Other neurology in Lacombe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →